Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia

Braz J Psychiatry. 2011 Sep;33(3):223-4. doi: 10.1590/s1516-44462011000300003.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antipsychotic Agents / therapeutic use*
  • Cyclic GMP / physiology*
  • Humans
  • Nitric Oxide / physiology*
  • Receptors, N-Methyl-D-Aspartate / physiology*
  • Schizophrenia / drug therapy*
  • Schizophrenia / etiology

Substances

  • Antipsychotic Agents
  • Receptors, N-Methyl-D-Aspartate
  • Nitric Oxide
  • Cyclic GMP